Saliva swab may predict weight loss drug success

NCT ID NCT06814938

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a biomarker found in saliva can predict how much weight people with obesity will lose when taking semaglutide. Researchers will compare weight changes in biomarker-positive and biomarker-negative participants over 24 weeks. The goal is to personalize obesity treatment, making it more effective and efficient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Semaglutide

What this could lead to

If successful, this could lead to a simple saliva test that tells doctors which patients will benefit most from semaglutide for weight loss.

What could go wrong

This is a small, early-stage study focused on prediction, not a new treatment. The biomarker may not reliably predict response in real-world settings.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States